More Jobs
Apply Now

Scientist I/II, In Vivo Pharmacology

Lexeo Therapeutics
New York City, New York, United States
Posted
On-site
$111.4K-150K/yr
Full-time
Entry-level
Job Description

Role Summary 

Lexeo is seeking a hands-on in vivo pharmacologist to build rodent models of cardiac disease and use them to de-risk targets, screen therapeutic candidates and advance our discovery pipeline. The scientist will design, perform or manage rodent studies from target validation through hit identification, working cross-functionally with In Vitro Pharmacology, Modality Engineering, and Translational Sciences to select-advance molecules. Reporting to the Head of Cardiac Research, this role joins cardiac, neuroscience, and non-clinical scientists developing therapies for genetic heart disease and offers broad experience in multidisciplinary biopharma research. 

Primary Responsibilities

  • Design and execute in vivo studies that de-risk novel targets, using genetic knockdown/overexpression and tool molecules to test target–phenotype links
  • Outsource or internally establish rodent cardiac disease models, including transgenic lines and surgical models such as TAC and MI
  • Run therapeutic screening studies that rank candidates on efficacy, dose-response, durability, and identify hit molecules for advancement
  • Dose by multiple routes (IV, IP, SC, IM, PO, retro-orbital) and by osmotic minipump across longitudinal studies
  • Lead study takedowns: necropsy, blood and tissue collection, and processing for histology, molecular, and ex vivo endpoints, including Langendorff cardiac dissociation
  • Partner with Translational Sciences to establish bioanalytical methods for biodistribution and target engagement in rodent tissues, and align on models with clinical endpoints/biomarkers
  • Analyze, interpret, and present data to project teams; keep study records in the ELN in line with IACUC and animal welfare standards
  • Manage study logistics, manage budgets, flag capacity or timeline risks early, and ideate novel methods for pharmacology and physiology 

Required Skills and Qualifications

  • PhD in physiology, pharmacology, cardiovascular biology, or a related field with 0–3 years of postdoctoral or industry experience; or MS with 5+ years of industry experience
  • Hands-on rodent experience: handling, multi-route dosing, blood collection, survival surgery, and necropsy
  • Track record using rodent disease models for target validation or efficacy testing of molecules
  • Proven understanding of power analyses, methods of randomizing animal models and appropriate uses of statistical methods
  • Strong data analysis skills (e.g., GraphPad) and clear written and verbal communication
  • Organized and independent; able to run several longitudinal studies at once within a collaborative team
  • Ability to regularly work onsite at HQ in New York City 

Preferred Skills and Qualifications

  • Industry experience in a small, fast-paced biotech is highly preferred
  • Working knowledge of qPCR/ddPCR for vector/mRNA, ELISA/LC-MS for ASO, RNAscope/IHC for tissue localization, WB/ ELISA/MSD for protein detection
  • Hands-on echocardiography in mice and rats (e.g., Vevo)
  • ECG and blood pressure telemetry implantation and analysis in mice and rats (e.g., Ponemah)
  • Cardiac surgical models (TAC, MI) and invasive hemodynamics (PV-loop)
  • Demonstrated experience with models of neurodegenerative disease, particularly ataxia or cerebellar disorders, including execution and interpretation of rotarod, gait analysis, balance beam, grip strength, and longitudinal behavioral studies
  • In vivo experience working with and advancing AAV or oligonucleotide therapeutics
  • Experience selecting and evaluating CROs to perform animal studies
  • AALAS certification or equivalent 

About LEXEO 

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need. 

LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.